About Yaso Therapeutics Inc.

Yaso is a biopharmaceutical company developing proprietary drug products to address unmet medical needs in the treatment of herpes, sexually transmitted diseases (STDs), and for unplanned pregnancy. Their focus is on creating novel therapeutic solutions for these conditions.

```xml <problem> Current treatments for herpes and gonorrhea face increasing challenges due to drug-resistant strains, while existing non-hormonal contraceptive options for women are limited in availability, safety, and efficacy. This creates a need for novel therapeutic and preventative solutions that address these unmet medical needs in sexual and reproductive health. </problem> <solution> Yaso Therapeutics is developing drug products containing PPCM (polyphenylene carboxymethylene), a novel polyanionic drug with broad activity against viruses and other pathogens. Their focus is on topical delivery to treat and prevent drug-resistant strains of gonorrhea and herpes simplex virus (HSV1 and HSV2), as well as to prevent unplanned pregnancies. PPCM has demonstrated in vitro antiviral efficacy against Ebola virus and SARS-CoV-2, suggesting potential applications beyond STIs and contraception. The company aims to provide women with non-hormonal contraceptives that are effective, safe, affordable, and accessible. </solution> <features> - Topical formulations containing PPCM for the treatment and prevention of herpes simplex virus (HSV1 and HSV2) - Drug products designed to combat all drug-resistant strains of gonorrhea - Non-hormonal contraceptive options for women - PPCM exhibits broad activity against viruses and other pathogens - Demonstrated in vitro antiviral efficacy against Ebola virus and SARS-CoV-2 - PPCM induces premature human acrosomal loss by Ca2+ signaling dysregulation </features> <target_audience> The primary target audience includes women seeking non-hormonal contraception, individuals at risk of or infected with herpes simplex virus or drug-resistant gonorrhea, and healthcare providers in the fields of sexual and reproductive health. </target_audience> ```

What does Yaso Therapeutics Inc. do?

Where is Yaso Therapeutics Inc. located?

Yaso Therapeutics Inc. is based in Frisco, United States.

Location

Frisco, United States

Employees

5 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Yaso Therapeutics Inc.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

yasotherapeutics.com 200+

Frisco, United States

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Current treatments for herpes and gonorrhea face increasing challenges due to drug-resistant strains, while existing non-hormonal contraceptive options for women are limited in availability, safety, and efficacy. This creates a need for novel therapeutic and preventative solutions that address these unmet medical needs in sexual and reproductive health.

Solution

Yaso Therapeutics is developing drug products containing PPCM (polyphenylene carboxymethylene), a novel polyanionic drug with broad activity against viruses and other pathogens. Their focus is on topical delivery to treat and prevent drug-resistant strains of gonorrhea and herpes simplex virus (HSV1 and HSV2), as well as to prevent unplanned pregnancies. PPCM has demonstrated in vitro antiviral efficacy against Ebola virus and SARS-CoV-2, suggesting potential applications beyond STIs and contraception. The company aims to provide women with non-hormonal contraceptives that are effective, safe, affordable, and accessible.

Features

Topical formulations containing PPCM for the treatment and prevention of herpes simplex virus (HSV1 and HSV2)

Drug products designed to combat all drug-resistant strains of gonorrhea

Non-hormonal contraceptive options for women

PPCM exhibits broad activity against viruses and other pathogens

Demonstrated in vitro antiviral efficacy against Ebola virus and SARS-CoV-2

PPCM induces premature human acrosomal loss by Ca2+ signaling dysregulation

Target Audience

The primary target audience includes women seeking non-hormonal contraception, individuals at risk of or infected with herpes simplex virus or drug-resistant gonorrhea, and healthcare providers in the fields of sexual and reproductive health.